Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

addiction

- PMLiVE

Merck’s backing of NGM Bio yields NASH drug deal

Drug has potential in diabetes treatment as well

- PMLiVE

Gilead NASH drug clears mid-stage trial, but rivals are looming

Positive results to challenge Intercept in emerging disease area

- PMLiVE

Novartis and Pfizer to collaborate on NASH combinations

Big pharma giants target nascent multi-billion market

Insights from the charity sector

Insights from the charity sector – from patient engagement to people-driven design

Marianne Guldbrandsen, Strategy Director at Cuttsy+Cuttsy and former Head of Innovation and Strategic Partnerships at Macmillan, discusses how people-driven research leads to truly patient-centred products and services, and what the...

Cuttsy + Cuttsy

- PMLiVE

Viking throws down gauntlet in NASH battle

Biotech is challenging rival Madrigal in 'next big thing' disease area

Gilead Sciences

Gilead targets hep B in half a billion dollar deal with Precision BioSciences

Biopharma looks to genome editing platform to discover hepatitis B cure

Patient Engagement for the Life Sciences

Patient Engagement for the Life Sciences, written by Guy Yeoman and Mitchell Silva with editorial and design support from Cuttsy+Cuttsy, explains the ‘why’ and the ‘how’ of patient engagement. It...

Cuttsy + Cuttsy

Patient Engagement Book Image

Moving away from pharma’s paternalistic approach

New handbook makes the case for greater patient engagement in the development of new medicines

Cuttsy + Cuttsy

Empowered patients improve outcomes

This white paper co-authored by our own Caroline Benson and Guy Yeoman, MediPaCe, discusses why non-adherence is occurring, how patients’ can be better engaged with their conditions and treatments and...

Cuttsy + Cuttsy

It’s nice, but it’s not an infographic

If you want to know if you’ve created an infographic, you can have a go with our flow diagram

Cuttsy + Cuttsy

- PMLiVE

AZ taps Ionis for another drug, this time in NASH

Will acquire the US pharma group’s antisense drug in a deal valued up to $330m

- PMLiVE

Six degrees of participation

Exploring the ongoing journey to patient empowerment and examining how pharma can play a part in more participatory models of care

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links